Drug/Device Combinations: A Union to Deliver the Best Medical Product to Patients

FDA Small Business Regulatory Education for Industry (REdI)
Silver Spring, MD
September 29, 2015

Kristina Lauritsen, Ph.D.
Product Jurisdictional Officer
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

James Bertram, Ph.D., RAC
Regulatory Advisor & Product Jurisdictional Officer
Office of Device Evaluation
Center for Devices and Radiological Health
U.S. Food and Drug Administration
Who are we?

• **Kristina Lauritsen**
  – CDER Product Jurisdiction Officer
  – [CDERProductJurisdiction@fda.hhs.gov](mailto:CDERProductJurisdiction@fda.hhs.gov) (preferred)
  – (301) 796-8936

• **James Bertram**
  – CDRH Product Jurisdiction Officer
  – [CDRHP productJurisdiction@fda.hhs.gov](mailto:CDRHP productJurisdiction@fda.hhs.gov) (preferred)
  – (301) 796-9588
What do we do?

- The Product Jurisdiction Officers in CDRH, CBER and CDER are liaisons to OCP for their Center
- Provide recommendations to OCP re: classification and assignment of combination and single-entity products
- Represent their Center on combination product and jurisdiction policies
- Work with OCP to develop guidance documents and regulations that affect their Center
What do we do?

- Participate in inter-center working groups
- Help sponsors clarify the regulatory pathway for products assigned to their Center
- Respond to internal and external inquiries
Learning Objectives

• Identify what is and isn’t a combination product

• Describe the Agency’s assignment of combination products

• Compare/contrast the regulatory paradigms for CDER/CDRH

• Recognize review considerations for combination products

• Understand best practices for combination products and navigating the FDA
First things first... What is a Combination Product?

Combinations of 2 or more **DIFFERENT** products:

- Drug + Device
- Device + Biologic
- Drug + Biologic
- Drug + Device + Biologic
Combination Product... How are they combined?

• 21 CFR 3.2(e)
  – Physically or chemically into a single entity
  – Co-packaged / Kit
  – Sold separately, but labeled for use together

• Examples
  – Drug-eluting stent
  – Kit w/bandages & antibiotic ointment
  – Photodynamic therapy
NOT Combination Products

- Drug-Drug
- Device-Device
- Biologic-Biologic
- Food + Drug/Device/Biologic
- Cosmetic + Drug/Device/Biologic
I have (or think I have) a Combination Product. Now what?

1. What am I? (product classification)
2. Where do I go? (product assignment)
3. What do I do when I get there? (regulatory pathway)
Office of Combination Products (OCP)

- Charged with assigning an FDA center to have primary jurisdiction for review of both combination and single entity (i.e., non-combination) products where jurisdiction is unclear or in dispute.

- Provides a focal point for combination product issues for internal / external stakeholders

- Has broad oversight responsibilities covering the regulatory life cycle of combination products
Remember…

• Non-combinations are assigned based on their classification:
  – Drug (FDCA 201(g)) - **CDER**
  – Device (FDCA 201(h)) - **CDRH**
  – Biological Product (PHSA 351(a)) – **CBER** or **CDER**

• Exceptions:
  – Devices that create a biologic at the point of care (devices regulated by CBER)
  – Therapeutic proteins, antibodies (biological products regulated by CDER)

*Combination Product ???*
Recall the Statute (FDCA 503(g))…

Combination products are assigned based on the primary mode of action (PMOA). If the Secretary determines that the primary mode of action is that of ---

(A) a drug (other than a biological product), the agency center charged with premarket review of drugs shall have primary jurisdiction, --- CDER

(B) a device, the agency center charged with premarket review of devices shall have primary jurisdiction, --- CDRH

(C) a biological product, the agency center charged with premarket review of biological products shall have primary jurisdiction. --- CBER or CDER
PMOA Examples

Drug Eluting Stent
- PMOA – stent opens artery (device)
- Secondary MOA – drug prevents inflammation and restenosis
- Assigned to CDRH

Drug Eluting Disk
- PMOA – chemotherapy for brain tumor (drug)
- Secondary MOA – local delivery of drug by the device
- Assigned to CDER
But…PMOA may be difficult to identify

- Early development (just don’t know)
- Two (or more) completely different modes of action, and neither is subordinate to the other

What happens next?
Assignment Algorithm

If unable to determine the PMOA with reasonable certainty, OCP will then consider...

• FIRST: Consistency
  – Assign the product to the Center that regulates other combination products that present similar questions of safety and effectiveness

• SECOND: Safety and Effectiveness
  – When FIRST does not apply, assign the product to the Center with the most expertise related to the most significant safety and effectiveness questions

(21 CFR 3.4)
Algorithm Assignment example

Contact lens coated with glaucoma drug
- MOA: Lens corrects vision
- MOA: Drug treats glaucoma
- Device and drug have independent modes of action
  - Tier 1 – no prior assignments of a contact lens + glaucoma drug
  - Tier 2 – the most significant safety and effectiveness questions relate to the clinical performance and characterization of the drug, while the questions related to the vision-correcting lens are considered more routine
- Product is assigned to CDER
How do I get a Classification / Jurisdiction Assignment?

• Informal guidance:
  – Email: combination@fda.gov
  – Simple issues, uncertainty, process concerns
  – Determine whether an RFD is needed
  – Non-binding; can submit RFD if disagree with informal guidance

• Formal process:
  – Submit a Request for Designation (RFD)
  – Formal, binding determination – 60 days
  – Complex issues or dispute / uncertainty
  – Requirements in 21 CFR 3.7
RFD process

- 15 page limit, including attachments
- Complete product description
- Amount and purpose of ingredients/components
- Indications for use
- Developmental work
- MOA and PMOA
  - How it works (mechanism), not just what it does
  - Rationale – supported by data, reference to literature
- Sponsor’s recommendation for classification / assignment
When to submit an RFD or informal inquiry?

Submit an RFD or informal inquiry **BEFORE** any submission (i.e., presubmission / pre-IND, marketing submission)

**Why?**
FDA may stay the review clock while a determination is being made (21 CFR 3.10)
Classification and rationale

Office of Combination 1
15800 Crabbs Branch Way
Suite 200
Rockville, MD 20855

Shepard Bentley, RAC

Carlsbad, CA 92010

Re: Request for Determination of Lead Center for
AWBAT Plus Wound Dressing

You recommend that the AWBAT Plus Dressings be assigned to CDRH because you believe the PMOA of the combination product is provided by the device components’ action to close the wound, while the additional components provide a secondary role in maintaining a moist wound-healing environment.

Product Classification: Combination Product

We have considered the information in the RFD and discussed the issues with staff from CDRH, the Center for Drug Evaluation and Research (CDER), and the Office of General Counsel (OGC).

Assignment and rationale

Assignment of Lead Center: CDRH

We have considered the information in the RFD, and discussed the issues with staff in CDRH and the Center for Drug Evaluation and Research (CDER). This product has two modes of action. One action of the product is that of the device components to provide a physical barrier. CDRH’s Plastic and Reconstructive Surgery Devices Branch (PRSDB) will be responsible for the combination product’s premarket review and regulation. For further information about...
What’s next?

Classification
Assignment
What do I do when I get there?

- Early Interactions and Feedback
- Clinical Trials
- Manufacturing
- Premarket Submissions
- Post-market Requirements
- Other Considerations
Product Development
Product Development

Early Interactions & Feedback
## CDRH- Early Interaction / Feedback

<table>
<thead>
<tr>
<th>Q-Submission Type</th>
<th>Meeting</th>
<th>Timeframe for Meeting/Teleconference/Feedback (from receipt of submission)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-Submission</strong></td>
<td>Upon request</td>
<td>75-90 days</td>
</tr>
<tr>
<td><strong>Informational Meeting</strong></td>
<td>Yes</td>
<td>90 days</td>
</tr>
<tr>
<td><strong>Study Risk Determination</strong></td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Agreement Meeting</strong></td>
<td>Yes</td>
<td>30 days or within time frame agreed to with sponsor</td>
</tr>
<tr>
<td><strong>Determination Meeting</strong></td>
<td>Yes</td>
<td>Scheduled within 30 days of request</td>
</tr>
<tr>
<td><strong>Submission Issue Meeting</strong></td>
<td>Yes</td>
<td>21 days</td>
</tr>
<tr>
<td><strong>Day 100 Meeting</strong></td>
<td>Yes</td>
<td>100 days (from filing of PMA)</td>
</tr>
</tbody>
</table>
# CDER- Early Interaction / Feedback

<table>
<thead>
<tr>
<th>Meeting Request</th>
<th>Meeting Topic</th>
<th>Timing of Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type A</strong></td>
<td>Stalled development, Dispute resolution, Clinical holds, Special Protocol Assessment (SPA)</td>
<td>Meet within 30 days of request (briefing package submitted 2 weeks ahead)</td>
</tr>
<tr>
<td><strong>Type B</strong></td>
<td>preIND, end of Phase (1)/2/3, preNDA/BLA</td>
<td>Meet within 60 days of request (briefing package submitted 4 weeks ahead)</td>
</tr>
<tr>
<td><strong>Type C</strong></td>
<td>Any other meeting</td>
<td>Meet within 75 days of request (briefing package submitted 4 weeks in advance)</td>
</tr>
</tbody>
</table>
Product Development

Clinical Trials
CDRH- Clinical Trials

• Investigational Device Exemption (IDE)
  – 21 CFR 812 - Procedures for conducting IDE
  – Often conducted in support of a PMA application and small percentage of 510(k)s
  – Feasibility Study
    • Early & Traditional feasibility studies
    • Capture preliminary safety and effectiveness (S&E) / Not statistically powered / Inform pivotal study design
  – Pivotal Study
    • Powered to collect definitive evidence on S&E
  – Early/Expanded Access
    • e.g., compassionate use, emergency use, continued access
CDER- Clinical Trials

• Investigational New Drug (IND) application
  – 21 CFR 312 - Procedures for conducting IND
  – Commercial / Research
  – Phase I – first in human, dose-ranging, early effectiveness (20-80 patients)
  – Phase II – well-controlled to establish probable effectiveness, side-effects (100-300 patients)
  – Phase III – expanded well-controlled study for effectiveness and safety (1000-2000 patients)
  – Phase IV – post-approval studies
Product Development

Manufacturing
CDRH/CDER- Manufacturing

- **CDRH**
  - Quality System Regulation (QSR)
  - 21 CFR 820

- **CDER**
  - Current Good Manufacturing Practices (cGMP)
  - 21 CFR 210, 211

- **Combination Product**
  - Streamlines requirements that would apply to each constituent part of combination product
  - Final Rule (1/22/2013) (codified in 21 CFR 4)
  - Draft Guidance (1/2015)- *Current Good Manufacturing Practice Requirements for Combination Products*
Product Development

Premarket Submissions

Early interactions
Clinical studies
Manufacturing
CDRH- Device Classification

- Devices are classified into Class I, II, or III
- Device classification is based on the controls necessary to provide a reasonable assurance of safety and effectiveness:
  - Class I – General Controls are sufficient
    - Most Class I Devices are also exempt from premarket notification (510(k)) requirements, and many are exempt from GMPs
  - Class II – General Controls and Special Controls are required (Typically require 510(k))
  - Class III – General controls and Premarket Approval are required (Typically require PMA)
CDRH- Premarket Submissions

- Premarket Notification (510(k)) [FDCA 510(k), 21 CFR 807]
  - “Clearance,” vast majority of device submissions, ~4,000/year
  - “Substantially equivalent” (at least as safe and effective)

- De Novo [513(f)(2)]
  - “Grant,” ~30/year
  - No valid predicate

- Premarket Approval (PMA), [FDCA 515, 21 CFR 814]
  - “Approval,”
  - Reasonable assurance of safety and effectiveness
  - Original PMAs ~40/year

- Humanitarian Device Exemption (HDE) [FDCA 510(m)(2), 21 CFR 814, Subpart H]
  - < 4,000 individuals in US/year
  - Exempt from effectiveness requirements of PMA
CDER- Premarket Submissions

• NDA - section 505 of the FDCA describes three types of new drug applications
  1. 505(b)(1) – full report of safety and effectiveness
  2. 505(b)(2) – full report of safety and effectives, but some data comes from studies not conducted by the applicant (e.g., published literature)
  3. 505(j) - identical in active ingredient, dosage form, use, route of administration, etc., to a previously approved product (abbreviated NDA or ANDA)

• BLA – section 351 of the PHS Act describes biologic license applications
User Fees

• No separate user fee paradigm for combination products

• Fees depend on type of application submitted (e.g., PMA vs NDA)
Product Development

Post-market Requirements
CDRH- Post-market

- Changes to your legally marketed device
  - PMA supplements
    - Panel Track- Typically a change in IFU or design requiring new clinical data
    - 180 day Supplement – various modifications (design change to trade name change)
    - Real-Time Supplement (90 days) – minor design change
    - 30 day notice/135 Day Supplement - manufacturing changes
  - 510(k)
    - Traditional - Affects indication for use or could affect S&E
    - Special - Does not affect the intended use of the device and does not alter the fundamental scientific technology of the device

- Adverse Event (AE) reporting (21 CFR 803) (both PMA & 510(k))
- PMA annual reports
CDER- Post-Market

• Changes to your NDA or ANDA
  – Manufacturing sites/process, specifications, container closure, labeling, etc.
    – major changes - Prior Approval Supplement
    – moderate changes - Changes Being Effected (CBE) supplement
      » CBE
      » CBE-30
    – minor changes - Annual reports

• Annual reports
• AE reporting (21 CFR 314)
Product Development

Other considerations
General Considerations

- No single developmental paradigm – NOT a one size fits all approach
- Existing guidance for constituent parts are a starting point only
- Need to address issues for product as a whole
- Very few combination product guidances:
  - Drug-eluting stents (*draft*)
  - Pen injectors
General Considerations

• Authorization to reference drug (DMF) or device (MAF) masterfiles
  – Permit the submission of proprietary information so that parties other than the owners of that information may rely on it

• Outstanding drug/device issues

• Only one investigational application for a combination product
Intercenter Consultation

• FDA reviewers are more aware of combination product review issues than ever before

• Formal intercenter consultation process: http://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm119234.htm

• Request specific input and expertise

• Center consultation and collaboration is ongoing throughout product life-cycle

• Lead center facilitates interactions with sponsor and consulting center
Inter-center Consultation Requests

*FY 13 Compared to 5-year average
Regulatory Challenges

• Jurisdiction
• Disparity in statutory and regulatory requirements between CDRH & CDER/CBER
• Learning curves – FDA and industry
• Appropriate leveraging of available information
• Appropriate pre-clinical testing and clinical trial design
• Regulatory and scientific approach for single-entity product ≠ device+drug/biologic
OCP can help!

- Manage the intercenter consult process to ensure timeliness of submission review
- Tracks and monitors all intercenter consult requests
- Facilitates any disputes between the centers regarding combination products
- Develops policies and processes for improving intercenter consultation
DES Case Study

Drug Eluting Stent

- PMOA – stent opens artery (device)
- Secondary MOA – drug prevents inflammation and restenosis
- Device/Drug constituent parts
- Assigned to CDRH
# Device Classification

<table>
<thead>
<tr>
<th>Device</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stent, Superficial Femoral Artery, Drug-Eluting</td>
<td>Stent, superficial femoral artery, drug-eluting — a metal scaffold with a drug coating placed via a delivery catheter into the superficial femoral artery artery to maintain the lumen. The drug coating is intended to inhibit restenosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Review Panel</th>
<th>Cardiovascular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Code</td>
<td>NIU</td>
</tr>
</tbody>
</table>

**Premarket Review**

- Office of Device Evaluation (ODE)
- Division of Cardiovascular Devices (DCD)
- Vascular Surgery Devices Branch (VSDB)

**Submission Type**

- PMA

**Device Class**

- 3

<table>
<thead>
<tr>
<th>Device</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary Drug-Eluting Stent</td>
<td>Stent, coronary, drug-eluting — a metal scaffold with a drug coating placed via a delivery catheter into the coronary artery or saphenous vein graft to maintain the lumen. The drug coating is intended to inhibit restenosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Review Panel</th>
<th>Cardiovascular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Code</td>
<td>NIQ</td>
</tr>
</tbody>
</table>

**Premarket Review**

- Office of Device Evaluation (ODE)
- Division of Cardiovascular Devices (DCD)
- Interventional Cardiology Devices Branch (ICDB)

**Submission Type**

- PMA

**Device Class**

- 3
Components of DES

- Device
  - Stent platform
  - Delivery device
- Drug
  - Active ingredient
- Polymer/carrier

Need a comprehensive evaluation of components AND finished combination product
Considerations from a preclinical perspective (bench testing)

Device
- Polymer coating integrity
- Particulate matter
- Simulated use
- Stent integrity
- Corrosion resistance
- Delivery system functionality
- Leachables / extractables
- Polymer & stent material chemistry
- Shelf life
- MR compatibility

Drug
- Chemistry (purity / impurities)
- Loading
- Elution profile (polymer/carrier)
- Toxicology (cell culture)
- Structure
- CMC
- Stability
Considerations from a preclinical perspective (in vivo / animal studies)

Device
- Biocompatibility
- Stent integrity and performance in clinically relevant model
- Handling characteristics (delivery / deployment)
- Compare / contrast bare metal to polymer coated to drug+polymer coated

Drug
- Local / regional / systemic toxicities (e.g., NOAEL)
- Dose ranging / finding studies
- Pharmacokinetics (PK) studies
- Acute / chronic exposure
Considerations from a clinical perspective

- Primary and secondary endpoints to support safety and effectiveness of the DES

- Additional Drug studies / parameters
  - Depends on previous experiences (NME, previously approved or studied under IND)
  - Depends on results from preclinical studies (e.g., IV administration of drug alone needed?)
  - IV dose escalation studies
  - Metabolic studies
  - Drug interaction studies
  - Release kinetics
Considerations from a manufacturing perspective

Device

- Specifications for device component(s)
- QSR (21 CFR 820)

Drug

- Specifications established to control quality of drug
- GMP (21 CFR 210/211)
Summary

• No single developmental paradigm – NOT a one size fits all approach

• Work with FDA early in your development process to establish jurisdiction / classification

• Review all applicable guidance documents

• Leverage available / existing data for constituent parts, while taking into consideration the product as a whole (e.g., synergistic effects)

• Recommend early interactions with the Agency when developing your combination product
Industry Education Resources

- Acts, Rules and Regulations
  http://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm109108.htm

- Combination Product Guidance documents (final and draft)
  http://www.fda.gov/RegulatoryInformation/Guidances/ucm122047.htm

- Office of Combination Products
  http://www.fda.gov/CombinationProducts/default.htm
References

- **Meetings/Presubmissions**
  - CDER/CBER: Formal Meetings Between the FDA and Sponsors or Applicants
  - CDRH: Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff

- **Changes to an Approved NDA or ANDA**

- **Current Good Manufacturing Practice Requirements for Combination Products (DRAFT)**

- **Drug-Eluting Stents (DRAFT)**
Abbreviations

- AE – adverse event
- ANDA – abbreviated new drug application
- BLA – biologic license application
- CBE – changes being effected
- CBER – Center for Biologics Evaluation and Research
- CDER – Center for Drug Evaluation and Research
- CDRH – Center for Devices and Radiological Health
- CFR – Code of Federal Regulations
- cGMP – current Good Manufacturing Practices
- DES – drug eluting stent
- FDA – Food and Drug Administration
- FDCA – Food, Drug, and Cosmetic Act
- HDE – Humanitarian Device Exemption
- IDE – Investigational Device Exemption
- IND – Investigational New Drug
- IV - intravenous
- MOA – mode of action
- NME – new molecular entity
- NDA – New Drug Application
- NOAEL – no observed adverse effect level
- OCP – Office of Combination Products
- OSMP – Office of Special Medical Programs
- PHSA – Public Health Services Act
- PK - pharmacokinetics
- PMA – premarket approval
- PMOA – primary mode of action
- QSR – quality systems regulations
- RFD – request for designation
Questions?

Please complete the session survey: surveymonkey.com/r/2015-Plenary